GW PHARMACEUTICALS PLC (NASDAQ:GWPH) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On January 7, 2019, GW Pharmaceuticals plc (the “Company”) released an updated corporate presentation, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 7.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing, regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.
Item 7.01 Financial Statements and Exhibits.
(d) Exhibits
GW PHARMACEUTICALS PLC Exhibit
EX-99.1 2 tv510454_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ©2019 GW Pharmaceuticals. All rights reserved. NASDAQ: GWPH Grace Living with Dravet syndrome,…
To view the full exhibit click here
About GW PHARMACEUTICALS PLC (NASDAQ:GWPH)
GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies. The Company operates through three segments: Commercial, Sativex Research and Development (Sativex R&D), and Pipeline Research and Development. The Commercial segment distributes and sells the Company’s commercial products. The Sativex R&D segment seeks to maximize the potential of Sativex through the development of indications. The Sativex R&D segment focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using the Company’s cannabinoid technology platform.
